Physician profile
Bruce H Yaffe
NPI 1801962881
$21,760.96
in general payments reported to CMS, 2019-2025
18 companies · $209 in 2025
The $209 reported for 2025 was more than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $182 · 2021: $97.14 · 2022: $346 · 2023: $225 · 2024: $468 · 2025: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $903.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $903.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $19,057.02 | 2019 | |
| Amarin Pharma, INC. | $416.00 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $377.88 | 2019-2024 | Trulance, Plenvu |
| Sanofi-Aventis U.S. LLC | $352.65 | 2019-2025 | |
| Allergan, INC. | $314.15 | 2019 | |
| Gilead Sciences, INC. | $267.77 | 2019 | |
| Abbvie INC. | $258.43 | 2020-2024 | Linzess, Viberzi |
| Idorsia Pharmaceuticals US INC | $157.82 | 2022-2024 | Quviviq |
| Amgen INC. | $124.34 | 2019 | |
| Glaxosmithkline, LLC. | $92.25 | 2022-2025 | Trelegy Ellipta |
| Csl Behring | $85.80 | 2022 | |
| Lilly USA, LLC | $64.17 | 2023-2024 | Mounjaro, Jardiance |
| Novo Nordisk INC | $59.86 | 2024-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $41.43 | 2023-2025 | Breztri |
| Inspire Medical Systems, INC. | $28.86 | 2024 | Inspire |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $26.42 | 2022 | |
| Genentech USA, INC. | $18.10 | 2022 | |
| Merck Sharp & Dohme LLC | $18.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Yaffe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.